
Shares of Capricor Therapeutics Inc. (NASDAQ: CAPR) are up Thursday after the company announced progress regarding one of its rare disease therapeutics. The biotech company’s stock jumped 18% immediately following the news.
What To Know: Capricor said it met with the U.S. Food and Drug Administration (FDA) to clarify the regulatory approval process for Deramiocel, the company’s investigational cell therapy for the treatment of Duchenne muscular dystrophy (DMD). The stock reached $7.32 on Thursday before pulling back a bit, according to Benzinga Pro.